Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...